Molnupiravir is a drug produced by the American company Merck in cooperation with the biotechnology company Ridgeback Biotherapeutics. It works by inhibiting the multiplication of the coronavirus. By the end of 2021, Merck was to produce tablets sufficient for 10 million treatment cycles, many of these deliveries have been purchased by individual countries and the first batches are reaching them. It turns out that also to Poland.
URGENT There are the first Polish victims of Omikron! They are two men. What connects them?
Who Can Get Molnupiravir, the COVID-19 Drug? We check!
“Experts recommend, in the current epidemiological situation, administering the drug Molnupiravir to people infected with SARS-Cov-2 with impaired immune response immediately after the diagnosis of the infection, but not later than 5 days after the appearance of symptoms” explains Katarzyna Kubicka-Żach from the Communications Office of the Ministry of Health And he adds that a drug can be administered in people receiving anti-cancer therapy, transplant patients taking immunosuppressants, advanced or untreated HIV infection, chronic dialysis for renal failure.
The official also adds that the first batches of the product are already distributed by the Government Strategic Reserves Agency to medical entities that submitted a demand.
Your child had covid? Take a look at his health! Maybe you need to test his sugar?
How does Molnupiravir, the COVID-19 drug work? Is it suitable for everyone?
Molnupiravir is an antiviral medicine registered in Europe as Lagevrio.
It works by interfering with the multiplication process of the virus in cells and causing mutations that lead to self-annihilation.
Research shows that when given at the right time and in the right doses halves the risk of hospitalization and death in people newly diagnosed with COVID-19.
Molnupiravir is not a medicine for everyone. According to the manufacturer’s instructions, it can be administered to adults within the first five days after confirming infection with the SARS-CoV-2 virus and provided that they have at least one risk factor for developing a severe course of the disease. Additionally, this drug is used in the mild to moderate form of COVID-19. If it gets worse, hospitalization will be necessary anyway.
Without saying goodbye and wake, with a sense of guilt and regret … This is how hundreds of thousands of Poles now face the realities of mourning during an epidemic